PROJECTS WORLDWIDE

iPrEXIPrEx_OLE_logo

iPrEX, carried out in Brazil (Fiocruz, UFRJ, and USP), was the first study of PrEP, which involved 2,499 HSH in Latin America, USA, South Africa, and Thailand. The participants, who took Truvada® via oral, had a rate 44% lower of infection by HIV when compared to those that took placebo. Among the patients with adhesion to the treatment, there was a reduction of 92% of the infections by HIV when compared to those volunteers with no detectable level of Truvada® in the visit of the study before the seroconversion.

For further information, access the website of the study: http://www.iprexole.com/indexpt.html

 

IPERGAY (França e Canadá)

ipergay

 

 

This study is assessing if the use of Truvada® for PrEP shall be continuous or upon demand.

 

For further information, access: http://hivnet.ubc.ca/clinical-studies/canadian-hiv-trials-database /ctn268/

 

http://www.ipergay.fr/

 

 

Proud (Inglaterra)

proud

This study is assessing if the use of Truvada® for PrEP shall be immediate or 12 months after the advisory.

For further information, access:

http://www.proud.mrc.ac.uk/proud_study_summary.aspx

PrEPare (EUA)

ProjectPrEParedLogo

 

This study is assessing of the use of Truvada® for PrEP in men that make sex with young men (15 to 22 years old).

For further information, access: http://www.projectprepare.net/

 

RELATED LINKS

AIDES, França – http://www.aides.org/en/what-prep-2089

PrEP in CDC, USA: http://www.cdc.gov/hiv/prevention/research/prep/

PrEP Watch, USA: http://prepwatch.org/

AIDS Map, USA: http://www.aidsmap.com/PrEP/cat/1623/

Department of Health, USAhttp://aids.gov/hiv-aids-basics/prevention/reduce-your-risk/pre-exposure-prophylaxis/

0 Shares